The Cancer Research Technology Program (CRTP) develops and implements emerging technology, cancer biology expertise and research capabilities to accomplish NCI research objectives. The CRTP is an outward-facing, multi-disciplinary hub purposed to enable the external cancer research community. A major focus of the CRTP is the NCI RAS Initiative with the goal to discover new therapeutic interventions against RAS-driven cancers. In addition, the CRTP hosts the Nanotechnology Characterization Laboratory (NCL) which performs and standardizes preclinical efficacy and toxicity testing of nanoparticles intended for cancer therapeutics and diagnostics, and the Antibody Characterization Lab (ACL) which characterizes monoclonal antibodies or other renewable affinity binding reagents for use in cancer related research. CRTP scientists also work collaboratively with intramural NCI investigators to provide research technologies and expertise.
- Work closely with a highly collaborative multidisciplinary team of chemists, biochemists, biophysicists, and cell and structural biologists at the NCI RAS Initiative to develop and optimize small-molecules for use as RAS inhibitors
- Work as part of the RAS Computational Chemistry (RCC) team
- Perform computational ligand discovery (virtual screens using docking software and a large virtual database of small molecules) against RAS using the structures of oncogenic RAS mutants, and RAS-complexes with various effectors and regulatory proteins
- Optimize hits using computational methods including chemical informatics methods and free-energy calculations
- Test (and aid in developing) new docking methods for improving our computational screening against RAS
- Present research findings within the group and at national meetings and publish findings in peer reviewed journals
- Possession of a Ph.D. in computational chemistry or computational biology (or related field) from an accredited college or university according to the Council for Higher Education Accreditation. (Additional qualifying experience may be substituted for the required education). Foreign degrees must be evaluated for U.S. equivalency
- Must be able to obtain and maintain a security clearance
- Expertise in structure-based drug design (SBDD), e.g. virtual screening, molecular docking, molecular dynamics simulations, free-energy calculations, computer-aided drug discovery, and/or cheminformatics
- Expertise in molecular docking software, e.g. UCSF DOCK, Autodock, Glide (Schrodinger), etc.
- Experience with molecular modelling and molecular dynamics software, e.g. AMBERr, NAMD, GROMACS, etc.
- Knowledge of scripting and computer languages, e.g. Python, Unix shell, R, C++, Fortran
- Experience of working with RAS/small GTPases
- Knowledge of biochemical and biophysical techniques (SPR, ITC, LC-MS, etc.) to characterize protein-small molecule binding interactions